Mereo BioPharma

31 articles with Mereo BioPharma

• Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development

  11/23/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, effective December 7, 2020.

• Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020

  11/16/2020

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Tuesday, November 24, to review the Company’s key pipeline programs including etigilimab for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease.

• Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference

  11/10/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time. A live audio webcast of the presentation can be accessed through the Inve

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, Oct. 22

  10/22/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

  10/20/2020

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced the appointment of Christine Fox, CPA, as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs.

• Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

  10/19/2020

  On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

• Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update

  9/29/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announces unaudited interim financial results for the six months ended June 30, 2020 and provides a corporate update.

• Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

  9/24/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to setrusumab for the treatment of osteogenesis imperfecta.

• Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

  8/25/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the initiation of a Phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease.

• Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development

  6/30/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the appointments of John Lewicki, PhD, as Chief Scientific Officer, and Ann Kapoun, PhD, as Senior Vice President of Translational Research and Development.

• Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019

  6/16/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced financial results for the 12 months ended December 31, 2019.

• Mereo BioPharma Announces Completion of $70 Million Private PlacementPlans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio

  6/4/2020

  Mereo BioPharma Group plc announces the completion of a $70 million private placement with a number of new and existing U.S based institutional and accredited investors.

• Business Update and Directorate Change

  3/27/2020

  Mereo BioPharma Group plc today provided a general business update, including a current assessment of the impact of  the coronavirus disease (COVID-19)  pandemic on the business. The Company also announced a directorate change. Business Update The Company has provided an update on the setrusumab and alve

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta

  2/28/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced the successful completion of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the development of setrusumab, an anti-sclerostin antibody, for the treatment of children and adolescents with osteogenesis imperfecta (“OI”)

• Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor

  2/19/2020

  Mereo BioPharma Group plc, "Mereo" or the "Company," announced that it has entered into a Securities Purchase Agreement with a new U.S.-based institutional healthcare investor.

• Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab

  2/12/2020

  LONDON and REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it is distributing approximately 1.2 cents cash per Contingent Value Right (“CVR”), a total of approximately $463,748, related to the $4 million upfront milestone payment from the global license agreement with Oncologie, Inc. (after deduction of costs, charges and expenditures) for the development and commercialization of navicixi

• 

  Clinical Catch-Up: January 13-17

  1/20/2020

  There were plenty of clinical trial announcements this week. Here's a look.
• 

  BioSpace Global Roundup, Jan. 16

  1/16/2020

  Companies from across the globe provide updates to their business and pipeline.